Welcome to BioSeeker Group!

Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target?

Additional Information

Published Date Mar 23, 2010
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 610
PDF Fact Sheet View Fact Sheet for the report Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target? in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in pancreatic cancer.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target?.

    To find out more about Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report comprises defined and up to date development strategies for 213 pancreatic cancer drugs within the portfolio of 137 investigators, from Ceased to Marketed. The report extensively analyses 171 identified targets of pancreatic cancer drugs, organized into 142 drug target profiles, and assesses them in pancreatic cancer.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in pancreatic cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any pancreatic cancer drug to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights 4
3 Methodologies 6
4 Table of Contents 8
4.1 List of Figures 17
4.2 List of Tables 17
5 Introduction 24
5.1 The Scope of this Report 24
5.2 Definitions 27
5.3 Abbreviations 27
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment 28
6.1 Drug Repositioning in Oncology 28
6.2 Introduction to Pancreatic Cancer Therapeutic Targets in Oncology 29
6.2.1 Carboxy-Lyase Activity Targets 31
6.2.2 Catalytic Activity Targets 32
6.2.3 Cell Adhesion Molecule Activity Targets 40
6.2.4 Chaperone Activity Targets 46
6.2.5 Cysteine-type Peptidase Activity Targets 47
6.2.6 Cytokine Activity Targets 51
6.2.7 DNA Binding Targets 56
6.2.8 DNA Repair Protein Targets 58
6.2.9 DNA Topoisomerase Activity Targets 59
6.2.10 DNA-Directed DNA Polymerase Activity Targets 62
6.2.11 Extracellular Ligand-Gated Ion Channel Activity Targets 68
6.2.12 Extracellular Matrix Structural Constituent Targets 70
6.2.13 G-Protein Coupled Receptor Activity Targets 72
6.2.14 Growth Factor Activity Targets 81
6.2.15 GTPase Activity Targets 85
6.2.16 Hormone Activity Targets 94
6.2.17 Hydrolase Activity Targets 95
6.2.18 Ion Channel Activity Targets 96
6.2.19 Kinase Activity Targets 97
6.2.20 Kinase Binding Targets 106
6.2.21 Kinase Regulator Activity Targets 107
6.2.22 Ligand-Dependent Nuclear Receptor Activity Targets 110
6.2.23 Ligase Activity Targets 111
6.2.24 Lipase Activity Targets 115
6.2.25 Lipid Phosphatase Activity Targets 116
6.2.26 Molecular Function Unknown Targets 117
6.2.27 Motor Activity Targets 123
6.2.28 Oxidoreductase Activity Targets 124
6.2.29 Peptidase Activity Targets 129
6.2.30 Peptide Hormone Targets 132
6.2.31 Peroxidase Activity Targets 133
6.2.32 Protein Binding Targets 134
6.2.33 Protein Serine/Threonine Kinase Activity Targets 135
6.2.34 Protein Threonine/Tyrosine Kinase Activity Targets 148
6.2.35 Protein Tyrosine Phosphatase Activity Targets 153
6.2.36 Protein-Tyrosine Kinase Activity Targets 160
6.2.37 Receptor Activity Targets 171
6.2.38 Receptor Binding Targets 185
6.2.39 Receptor Signaling Complex Scaffold Activity Targets 189
6.2.40 RNA-Directed DNA Polymerase Activity Targets 193
6.2.41 Serine-Type Peptidase Activity Targets 194
6.2.42 Structural Constituent of Cytoskeleton Targets 198
6.2.43 Structural Molecule Activity Targets 199
6.2.44 Transcription Factor Activity Targets 200
6.2.45 Transcription Regulator Activity Targets 212
6.2.46 Transferase Activity Targets 217
6.2.47 Translation Regulator Activity Targets 218
6.2.48 Transmembrane Receptor Activity Targets 220
6.2.49 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 223
6.2.50 Transporter Activity Targets 250
6.2.51 Unclassified Targets 255
6.2.52 Voltage-Gated Ion Channel Activity Targets 256
6.3 The Cancer Genome Project and Pancreatic Cancer Therapeutic Targets 257
6.3.1 Pancreatic Cancer Therapeutic Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 257
6.4 Structure-based Drug Design in Pancreatic Cancer Therapeutics is Stimulated by Available Structure Data on Biological Targets 261
6.5 Target-Target Interactions among Identified Therapeutics Targets in Pancreatic Cancer 264
6.6 The Drug-Target Interactome 269
6.7 Protein Expression Levels of Identified Targets of Pancreatic Cancer Drugs 272
6.8 Pathway Assessment of Pancreatic Cancer Therapeutic Targets 276
6.8.1 Tools for Analysis of Cancer Pathways 277
6.8.2 Pathway Assessment 278
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Pancreatic Cancer Therapeutic Pipeline? 333
7.1 Terminated Drug Target Profiles of Pancreatic Cancer Drugs 335
7.2 Marketed: New and Unique Drug Target Profiles of Pancreatic Cancer Therapeutics 338
7.3 Phase III Clinical Development: New and Unique Drug Target Profiles of Pancreatic Cancer Therapeutics 339
7.4 Phase II Clinical Development: New and Unique Drug Target Profiles of Pancreatic Cancer Therapeutics 341
7.5 Phase I Clinical Development: New and Unique Drug Target Profiles of Pancreatic Cancer Therapeutics 345
7.6 Preclinical Development: New and Unique Drug Target Profiles of Pancreatic Cancer Therapeutics 348
7.7 No Development Data: New and Unique Drug Target Profiles of Pancreatic Cancer Therapeutics 350
7.8 Development Profiles of All Pancreatic Cancer Drugs in Oncology 352
7.9 The Competition Through Close Mechanistic Approximation of Pancreatic Cancer Therapeutics 370
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy 374
8.1 Small Molecules 376
8.1.1 Background 376
8.1.2 Target Profiles of Small Molecular Drugs 377
8.2 Peptide/Protein Drugs 386
8.2.1 Background 386
8.2.2 Target Profiles of Peptide and Protein Drugs 387
8.3 Antibodies and Antibody-like Structures 390
8.3.1 Background 390
8.3.2 Target Profiles of Antibody Drugs 390
8.4 Nucleic Acid Therapies 394
8.4.1 Background 394
8.4.2 Target Profiles of Nucleic Acid Drugs 395
8.5 Cell and Gene Therapy 396
8.5.1 Background 396
8.5.2 Target Profiles of Cell- and Gene Therapy Drugs 397
8.6 Drug Delivery and Nanotechnology 399
8.6.1 Background 399
8.6.2 Target Profiles of Reformulated Drugs 399
8.7 Compound Strategies based on Sub-Cellular Localization of Pancreatic Cancer Drug Targets 401
9 Pipeline and Portfolio Planning: Competitive Benchmarking of Pancreatic Cancer Cancer Therapeutic Pipeline by Investigator 408
9.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 408
9.2 Competitive Fall-Out Assessment 409
9.3 AB Science 411
9.4 Abraxis BioScience 412
9.5 Active Biotech 413
9.6 Adherex 414
9.7 Aduro BioTech 415
9.8 Advantagene 416
9.9 Advaxis 417
9.10 AEgera 419
9.11 Aeterna Zentaris 420
9.12 Aida Pharmaceuticals 421
9.13 Amgen 423
9.14 Antisense Pharma 425
9.15 Apotex 426
9.16 Archer Biosciences 427
9.17 Ariad 428
9.18 ArQule 429
9.19 Array BioPharma 431
9.20 Astellas 433
9.21 AstraZeneca 435
9.22 AVI BioPharma 439
9.23 Bayer 440
9.24 Biogen Idec 442
9.25 Bionovo 443
9.26 BioNumerik 444
9.27 BioVex 446
9.28 Boehringer Ingelheim 447
9.29 Bristol-Myers Squibb 448
9.30 BTG 451
9.31 Cell Genesys 452
9.32 Cell Therapeutics 453
9.33 Celldex Therapeutics 455
9.34 Celsion 456
9.35 Celtic Pharma 457
9.36 Center of Molecular Immunology 458
9.37 Cephalon 459
9.38 CG Therapeutics 460
9.39 CompleGen 461
9.40 Cornerstone Pharmaceuticals 462
9.41 Crititech 463
9.42 Cyclacel 464
9.43 Cynvec 465
9.44 CytImmune Sciences 466
9.45 Cytokinetics 467
9.46 Daiichi Sankyo 468
9.47 Dara Biosciences 471
9.48 EGEN Inc 472
9.49 Eisai 473
9.50 Elan 476
9.51 Eli Lilly 477
9.52 Epeius Biotechnologies 480
9.53 EpiCept 481
9.54 Facet Biotech 483
9.55 FibroGen 484
9.56 Genta 485
9.57 GenVec 486
9.58 Genzyme 487
9.59 GlaxoSmithKline 489
9.60 Gloucester Pharmaceuticals 492
9.61 GlycoGenesys 493
9.62 Hana Biosciences 494
9.63 Hoffmann-La Roche 495
9.64 Human Genome Sciences 499
9.65 ImmunoCellular Therapeutics 500
9.66 Immunomedics 501
9.67 Immutep 503
9.68 Innate Pharma 504
9.69 Innovive 505
9.70 Introgen Therapeutics 506
9.71 Ipsen 507
9.72 Johnson & Johnson 509
9.73 Kyowa Hakko Kirin 511
9.74 MBiotec 512
9.75 MediGene 513
9.76 Medisyn Technologies 515
9.77 Merck & Co 516
9.78 Merck KGaA 517
9.79 MethylGene 519
9.80 Micromet 520
9.81 Nektar Therapeutics 521
9.82 NeoPharm 522
9.83 Nippon Kayaku 525
9.84 Nippon Shinyaku 526
9.85 Non-industrial Sources 527
9.86 Novacea 528
9.87 Novartis 529
9.88 Novogen 533
9.89 OncoTherapy Science 534
9.90 Oncothyreon 535
9.91 OSI Pharmaceuticals 536
9.92 Oxford BioMedica 538
9.93 OXiGENE 539
9.94 Paladin Labs 540
9.95 PanaGin 541
9.96 Patrys 542
9.97 Pepscan Systems 544
9.98 Pfizer 545
9.99 Pharmacyclics 550
9.100 PharmaEngine 551
9.101 PharmaMar 552
9.102 Pharmexa 553
9.103 Pierre Fabre 554
9.104 Piramal 555
9.105 Pro-Pharmaceuticals 556
9.106 Ras Therapeutics 557
9.107 Reata Pharmaceuticals 558
9.108 Regeneron 559
9.109 Regulon 560
9.110 RESprotect 561
9.111 Rexahn 562
9.112 Rottapharm 563
9.113 Samyang 564
9.114 Sanofi-Aventis 566
9.115 Santaris Pharma 569
9.116 Shire 570
9.117 SuperGen 571
9.118 Taiho 573
9.119 Takeda 575
9.120 Tau Therapeutics 576
9.121 Thallion Pharmaceuticals 577
9.122 Therion Biologics 579
9.123 Titan Pharmaceuticals 580
9.124 TopoTarget 581
9.125 Tragara Pharmaceuticals 582
9.126 Trion Pharma 583
9.127 UMN Pharma 584
9.128 VaxOnco 585
9.129 Vertex Pharmaceuticals 586
9.130 Vion Pharmaceuticals 587
9.131 VioQuest 588
9.132 ViroMed 590
9.133 Voyager Pharmaceutical 591
9.134 Wilex 592
9.135 Xerion 594
9.136 Yakult Honsha 595
9.137 YM BioSciences 597
9.138 Zeria 598
9.139 Zhejiang Beta Pharma 599
10 Disclaimer 600
11 Drug Index 601
12 Company Index 606

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Pancreatic Cancer Drugs 268
Figure 2: The Drug-Protein Interactome of Pancreatic Cancer Drugs 270
Figure 3: Head-to-Head Targeting Interactome of Pancreatic Cancer Drugs 271
Figure 4: Distribution of Compound Types among Pancreatic Cancer Drugs 401
Figure 5: Primary Sub-cellular Localization of Drug Targets 402

4.2 List of Tables
Table 1: Head to Head Target Competition among Pancreatic Cancer Drugs 24
Table 2: Overall Breakdown of the Included Pancreatic Cancer Pipeline by Stage of Development 24
Table 3: Overview of Drug Target Profile Themes 29
Table 4: Terminally Ceased Therapeutic Pancreatic Cancer Targets 30
Table 5: Drug Targets of Pancreatic Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 258
Table 6: Identity of Pancreatic Cancer Drug Targets with Available Biological Structures 262
Table 7: Number of Target-Target Interactions among Targets of Pancreatic Cancer Drugs 264
Table 8: Pancreatic Cancer Drug Targets with Available Protein Expression Profiles 272
Table 9: Pathway Summary 278
Table 10: Drug Targets without any Identified Assigned Pathways 278
Table 11: Pathway Profiles According to BioCarta of Pancreatic Cancer Drug Targets 280
Table 12: Pathway Profiles According to KEGG of Pancreatic Cancer Drug Targets 302
Table 13: Pathway Profiles According to NetPath of Pancreatic Cancer Drug Targets 327
Table 14: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness 333
Table 15: Top Competitive Target Profiles in Pancreatic Cancer 334
Table 16: Terminated Drug Target Strategies of Pancreatic Cancer Drugs 335
Table 17 New and Unique Pancreatic Cancer Target Strategies Being Marketed 338
Table 18: The Competition Through Close Mechanistic Approximation Between Marketed Drugs in Pancreatic Cancer 338
Table 19: New and Unique Pancreatic Cancer Target Strategies in Phase III Clinical Development 339
Table 20: The Competition Through Close Mechanistic Approximation Between Phase III Drugs in Pancreatic Cancer 340
Table 21: New and Unique Pancreatic Cancer Target Strategies in Phase II Clinical Development 341
Table 22: The Competition Through Close Mechanistic Approximation Between Phase II Drugs in Pancreatic Cancer 343
Table 23 New and Unique Pancreatic Cancer Target Strategies in Phase I Clinical Development 345
Table 24: The Competition Through Close Mechanistic Approximation Between Phase I Drugs in Pancreatic Cancer 346
Table 25: New and Unique Pancreatic Cancer Target Strategies in Preclinical Development 348
Table 26: The Competition Through Close Mechanistic Approximation Between Preclinical Drugs in Pancreatic Cancer 349
Table 27: New and Unique Pancreatic Cancer Target Strategies in Unknown Developmental Stage 350
Table 28: The Competition Through Close Mechanistic Approximation Between Drugs with no Developmental Data in Pancreatic Cancer 351
Table 29: The Progression, Maturity and Competitive Comparison of Target Profiles in Pancreatic Cancer Drug Development 352
Table 30: The Competition Through Close Mechanistic Approximation Among All Drugs in Pancreatic Cancer 370
Table 31: Overview of Compound Strategy Competition Among Pancreatic Cancer Drugs in Oncology 375
Table 32: Overview of the Competitive Landscape of Small Molecular Pancreatic Cancer Drugs 377
Table 33: The Competition Through Close Mechanistic Approximation between Small Molecule Drugs in Pancreatic Cancer 378
Table 34: Competitive Comparison of Target Profiles of Small Molecule Drugs in Pancreatic Cancer 380
Table 35: Overview of the Competitive Landscape of Peptide Based Pancreatic Cancer Drugs 387
Table 36: The Competition Through Close Mechanistic Approximation between Peptide Based Drugs in Pancreatic Cancer 387
Table 37: Competitive Comparison of Target Profiles of Peptide Based Drugs in Pancreatic Cancer 388
Table 38: Overview of the Competitive Landscape of Protein Based Drugs in Pancreatic Cancer 389
Table 39: Competitive Comparison of Target Profiles of Protein Based Drugs in Pancreatic Cancer 389
Table 40: Overview of the Competitive Landscape of Antibody Drugs in Pancreatic Cancer 390
Table 41: The Competition Through Close Mechanistic Approximation between Antibody Drugs in Pancreatic Cancer 391
Table 42: Competitive Comparison of Target Profiles of Antibody Drugs in Pancreatic Cancer 392
Table 43: Overview of the Competitive Landscape of Nucleic Acid Therapy Drugs in Pancreatic Cancer 395
Table 44: The Competition Through Close Mechanistic Approximation between Nucleic Acid Therapy Drugs in Pancreatic Cancer 395
Table 45: Competitive Comparison of Target Profiles of Nucleic Acid Drugs in Pancreatic Cancer 395
Table 46: Potential Forms of Cell Therapy 396
Table 47: Vectors in Gene Therapy 397
Table 48: Competitive Comparison of Target Profiles of Cell Therapy Based Drugs in Pancreatic Cancer 397
Table 49: Overview of the Competitive Landscape of Gene Therapy based Drugs in Pancreatic Cancer 397
Table 50: The Competition Through Close Mechanistic Approximation between Gene Therapy Drugs in Pancreatic Cancer 398
Table 51: Competitive Comparison of Target Profiles of Gene Therapy Based Drugs in Pancreatic Cancer 398
Table 52:Overview of the Competitive Landscape of Reformulated Drugs in Pancreatic Cancer 399
Table 53: The Competition Through Close Mechanistic Approximation between Reformulated Drugs in Pancreatic Cancer 400
Table 54: Competitive Comparison of Target Profiles of Reformulated Drugs in Pancreatic Cancer 400
Table 55: Compound Strategies based on Sub-Cellular Localization of Pancreatic Cancer Drug Targets 402
Table 56: Summary Table of Changes in the Competitive Landscape of Pancreatic Cancer Drug Development 408
Table 57: AB Science’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 411
Table 58: Abraxis BioScience’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 412
Table 59: Active Biotech’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 413
Table 60: Adherex’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 414
Table 61: Aduro BioTech’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 415
Table 62: Advantagene’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 416
Table 63: Advaxis’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 417
Table 64: AEgera’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 419
Table 65: Aeterna Zentaris’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 420
Table 66: Aida Pharmaceuticals’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 421
Table 67: Amgen’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 423
Table 68: Antisense Pharma’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 425
Table 69: Apotex’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 426
Table 70: Archer Biosciences’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 427
Table 71: Ariad’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 428
Table 72: ArQule’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 429
Table 73: Array BioPharma’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 431
Table 74: Astellas’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 433
Table 75: AstraZeneca’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 435
Table 76: AVI BioPharma’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 439
Table 77: Bayer’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 440
Table 78: Biogen Idec’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 442
Table 79: Bionovo’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 443
Table 80: BioNumerik’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 444
Table 81: BioVex’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 446
Table 82: Boehringer Ingelheim’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 447
Table 83: Bristol-Myers Squibb’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 448
Table 84: BTG’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 451
Table 85: Cell Genesys’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 452
Table 86: Cell Therapeutics’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 453
Table 87: Celldex Therapeutics’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 455
Table 88: Celsion’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 456
Table 89: Celtic Pharma’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 457
Table 90: Center of Molecular Immunology’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 458
Table 91: Cephalon’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 459
Table 92: CG Therapeutics’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 460
Table 93: CompleGen’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 461
Table 94: Cornerstone Pharmaceuticals’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 462
Table 95: Crititech’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 463
Table 96: Cyclacel’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 464
Table 97: Cynvec’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 465
Table 98: CytImmune Sciences’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 466
Table 99: Cytokinetics’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 467
Table 100: Daiichi Sankyo’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 468
Table 101: Dara Biosciences’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 471
Table 102: EGEN Inc’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 472
Table 103: Eisai’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 473
Table 104: Elan’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 476
Table 105: Eli Lilly’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 477
Table 106: Epeius Biotechnologies’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 480
Table 107: EpiCept’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 481
Table 108: Facet Biotech’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 483
Table 109: FibroGen’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 484
Table 110: Genta’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 485
Table 111: GenVec’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 486
Table 112: Genzyme’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 487
Table 113: GlaxoSmithKline’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 489
Table 114: Gloucester Pharmaceuticals’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 492
Table 115: GlycoGenesys’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 493
Table 116: Hana Biosciences’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 494
Table 117: Hoffmann-La Roche’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 495
Table 118: Human Genome Sciences’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 499
Table 119: ImmunoCellular Therapeutics’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 500
Table 120: Immunomedics’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 501
Table 121: Immutep’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 503
Table 122: Innate Pharma’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 504
Table 123: Innovive’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 505
Table 124: Introgen Therapeutics’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 506
Table 125: Ipsen’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 507
Table 126: Johnson & Johnson’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 509
Table 127: Kyowa Hakko Kirin’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 511
Table 128: MBiotec’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 512
Table 129: MediGene’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 513
Table 130: Medisyn Technologies’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 515
Table 131: Merck & Co’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 516
Table 132: Merck KGaA’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 517
Table 133: MethylGene’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 519
Table 134: Micromet’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 520
Table 135: Nektar Therapeutics’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 521
Table 136: NeoPharm’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 522
Table 137: Nippon Kayaku’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 525
Table 138: Nippon Shinyaku’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 526
Table 139: Non-industrial source’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 527
Table 140: Novacea’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 528
Table 141: Novartis’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 529
Table 142: Novogen’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 533
Table 143: OncoTherapy Science’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 534
Table 144: Oncothyreon’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 535
Table 145: OSI Pharmaceuticals’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 536
Table 146: Oxford BioMedica’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 538
Table 147: OXiGENE’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 539
Table 148: Paladin Labs’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 540
Table 149: PanaGin’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 541
Table 150: Patrys’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 542
Table 151: Pepscan Systems’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 544
Table 152: Pfizer’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 545
Table 153: Pharmacyclics’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 550
Table 154: PharmaEngine’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 551
Table 155: PharmaMar’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 552
Table 156: Pharmexa’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 553
Table 157: Pierre Fabre’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 554
Table 158: Piramal’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 555
Table 159: Pro-Pharmaceuticals’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 556
Table 160: Ras Therapeutics’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 557
Table 161: Reata Pharmaceuticals’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 558
Table 162: Regeneron’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 559
Table 163: Regulon’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 560
Table 164: RESprotect’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 561
Table 165: Rexahn’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 562
Table 166: Rottapharm’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 563
Table 167: Samyang’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 564
Table 168: Sanofi-Aventis’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 566
Table 169: Santaris Pharma’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 569
Table 170: Shire’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 570
Table 171: SuperGen’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 571
Table 172: Taiho’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 573
Table 173: Takeda’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 575
Table 174: Tau Therapeutics’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 576
Table 175: Thallion Pharmaceuticals’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 577
Table 176: Therion Biologics’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 579
Table 177: Titan Pharmaceuticals’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 580
Table 178: TopoTarget’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 581
Table 179: Tragara Pharmaceuticals’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 582
Table 180: Trion Pharma’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 583
Table 181: UMN Pharma’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 584
Table 182: VaxOnco’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 585
Table 183: Vertex Pharmaceuticals’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 586
Table 184: Vion Pharmaceuticals’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 587
Table 185: VioQuest’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 588
Table 186: ViroMed’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 590
Table 187: Voyager Pharmaceutical’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 591
Table 188: Wilex’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 592
Table 189: Xerion’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 594
Table 190: Yakult Honsha’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 595
Table 191: YM BioSciences’ Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 597
Table 192: Zeria’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 598
Table 193: Zhejiang Beta Pharma’s Included Drug Pipeline in Pancreatic Cancer and Competitive Fall-Out 599

This report includes 137 investigators plus their collaborators:
AB Science
Abraxis BioScience
Active Biotech
Adherex
Aduro BioTech
Advantagene
Advaxis
AEgera
Aeterna Zentaris
Aida Pharmaceuticals
Amgen
Antisense Pharma
Apotex
Archer Biosciences
Ariad
ArQule
Array BioPharma
Astellas
AstraZeneca
AVI BioPharma
Bayer
Biogen Idec
Bionovo
BioNumerik
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Cell Genesys
Cell Therapeutics
Celldex Therapeutics
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
CompleGen
Cornerstone Pharmaceuticals
Crititech
Cyclacel
Cynvec
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Dara Biosciences
EGEN Inc
Eisai
Elan
Eli Lilly
Epeius Biotechnologies
EpiCept
Facet Biotech
FibroGen
Genta
GenVec
Genzyme
GlaxoSmithKline
Gloucester Pharmaceuticals
GlycoGenesys
Hana Biosciences
Hoffmann-La Roche
Human Genome Sciences
ImmunoCellular Therapeutics
Immunomedics
Immutep
Innate Pharma
Innovive
Introgen Therapeutics
Ipsen
Johnson & Johnson
Kyowa Hakko Kirin
MBiotec
MediGene
Medisyn Technologies
Merck & Co
Merck KGaA
MethylGene
Micromet
Nektar Therapeutics
NeoPharm
Nippon Kayaku
Nippon Shinyaku
Novacea
Novartis
Novogen
OncoTherapy Science
Oncothyreon
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Patrys
Pepscan Systems
Pfizer
Pharmacyclics
PharmaEngine
PharmaMar
Pharmexa
Pierre Fabre
Piramal
Pro-Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Regeneron
Regulon
RESprotect
Rexahn
Rottapharm
Samyang
Sanofi-Aventis
Santaris Pharma
Shire
SuperGen
Taiho
Takeda
Tau Therapeutics
Thallion Pharmaceuticals
Therion Biologics
Titan Pharmaceuticals
TopoTarget
Tragara Pharmaceuticals
Trion Pharma
UMN Pharma
VaxOnco
Vertex Pharmaceuticals
Wilex
Vion Pharmaceuticals
VioQuest
ViroMed
Voyager Pharmaceutical
Xerion
Yakult Honsha
YM BioSciences
Zeria
Zhejiang Beta Pharma
This report includes 213 pancreatic cancer drugs. From Ceased to Marketed.
A shortlist of drugs included are:
aflibercept
bevacizumab
brivudine
capecitabine
catumaxomab
cetuximab
erlotinib
everolimus
golnerminogene pradenovec
GV-1001
larotaxel
masitinib
nadroparin
nimotuzumab
OTS-102
paclitaxel-1
sunitinib malate
tegafur + uracil
TS-1

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target?.
    To find out more about Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?
This report is an important part of creating and implementing a market development plan for any cancer therapeutic peptide drugs to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More


Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
This report is written for you to identify your competition and understand which targeting strategies are at work within anti-angiogenic drug development in oncology. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversly it may reveal unexpected competition for you. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Lymphoma and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lymphoma and by the mechanism/target/effect of Apoptosis. Learn More


Target Atlas in Ovarian Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More